BioCryst said today it halted patient enrollment in a Phase III trial of its flu drug candidate peramivir. In a statement, the company cited an interim analysis by its data monitoring committee that found just a small difference between peramivir and control groups for the primary endpoint, changes to vital signs and oxygen saturation through [...]
↧